
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

April 5, 2011 (April 5, 2011)

HARRIS & HARRIS GROUP, INC.

(Exact name of registrant as specified in its charter)

New York
(State or other jurisdiction of
incorporation)

0-11576
(Commission File
Number)

13-3119827
(IRS Employer
Identification No.)

1450 Broadway
New York, New York 10018

(Address of principal executive offices and zip code)

(212) 582-0900

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

On April 5, 2011, Harris & Harris Group, Inc. (the "Company") announced it invested \$2 million yesterday in Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc. (OTC: CSBR) ("Champions") as part of a private placement of 12.5 million shares of its common stock at a price of \$0.75 per share, resulting in gross proceeds to Champions of \$9.4 million.

The Company's press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

- (a) Not applicable.
- (b) Not applicable.
- (c) Not applicable.
- (d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated April 5, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 5,
2011

HARRIS & HARRIS GROUP, INC.

By: /s/ Daniel B. Wolfe
Daniel B. Wolfe
President

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated April 5, 2011

PRESS RELEASE

HARRIS & HARRIS GROUP, INC.®
1450 BROADWAY, 24TH FLOOR
NEW YORK, NY 10018
TEL. NO. (212) 582-0900

FOR IMMEDIATE RELEASE

APRIL 5, 2011

CONTACT: DANIEL B. WOLFE

HARRIS & HARRIS GROUP ANNOUNCES EQUITY INVESTMENT IN CHAMPIONS ONCOLOGY

Harris & Harris Group, Inc. (NASDAQ:TINY), announced it invested \$2 million yesterday in Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc. (“Champions”) (OTC: CSBR), as part of a private placement of 12.5 million shares of its common stock at a price of \$0.75 per share, resulting in gross proceeds to Champions of \$9.4 million.

The investor group consists of several institutional investors, including Battery Venture Group, Harris & Harris Group, Inc., and Perceptive Advisors, LLC. Champions’ Chief Executive Officer, Joel Ackerman, and President, Ronnie Morris, also participated in the financing. Champions’ press release may be viewed at <http://www.prnewswire.com/news-releases/champions-oncology-formerly-champions-biotechnology-completes-94-million-financing-119241874.html>.

Champions Oncology, Inc., is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. Champions’ Tumorgraft™ Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts™, in a manner that preserves the biological characteristics of the original human tumor. Champions offers personalized Tumorgraft™ development, drug studies and genome sequencing as part of its Personalized Oncology Solutions (“POS”) whereby physicians can evaluate the effects of cancer drugs on their patients’ Tumorgrafts™ and understand the genetic make-up of their patient’s tumor, enabling them to better select treatment regimens that may be efficacious to the patient. In addition, Champions provides to oncologists and their patients expert tumor panels to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients’ cancer tissues, as appropriate.

Harris & Harris Group is a publicly traded venture capital company that invests in nanotechnology and microsystems. Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com.

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company’s current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company’s business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company’s actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references to the websites www.HHVC.com and www.prnewswire.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the contents of third party websites.
